Vanguard Capital Management
NAUT icon

Vanguard Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Vanguard Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77M Buy
2,549,979
+4,382
+0.2% +$11.6K ﹤0.01% 3141
2026
Q1 		$9.88M Buy
+2,545,597
New +$6.26M ﹤0.01% 2736

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Capital Management's NAUT Position: Q2 2026 in Review

Vanguard Capital Management increased its Nautilus Biotechnolgy (NAUT) stake by 0.17% in Q2 2026, buying an estimated $11.6K and bringing the position to 2,549,979 shares worth $4.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3141.

Vanguard Capital Management first reported a position in NAUT in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.88M in Q1 2026. 92 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Vanguard Capital Management held 2,549,979 shares of Nautilus Biotechnolgy worth $4.77M as of Q2 2026.
  • Vanguard Capital Management bought 4,382 Nautilus Biotechnolgy shares in Q2 2026, an estimated $11.6K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3141 holding.
  • Vanguard Capital Management first reported a position in Nautilus Biotechnolgy in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Nautilus Biotechnolgy position peaked at $9.88M in Q1 2026.
  • 92 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.